280 related articles for article (PubMed ID: 24492364)
1. CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
Manosuthi W; Sukasem C; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
Antimicrob Agents Chemother; 2014; 58(4):2268-73. PubMed ID: 24492364
[TBL] [Abstract][Full Text] [Related]
2. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
Sukasem C; Cressey TR; Prapaithong P; Tawon Y; Pasomsub E; Srichunrusami C; Jantararoungtong T; Lallement M; Chantratita W
Br J Clin Pharmacol; 2012 Dec; 74(6):1005-12. PubMed ID: 22471906
[TBL] [Abstract][Full Text] [Related]
4. CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy.
Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
Int J Antimicrob Agents; 2014 Mar; 43(3):292-6. PubMed ID: 24359841
[TBL] [Abstract][Full Text] [Related]
5. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
[TBL] [Abstract][Full Text] [Related]
6. High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections.
Sukasem C; Chamnanphon M; Koomdee N; Puangpetch A; Santon S; Jantararoungtong T; Prommas S; Chantratita W; Manosuthi W
Drug Metab Pharmacokinet; 2013; 28(5):391-7. PubMed ID: 23399569
[TBL] [Abstract][Full Text] [Related]
7. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.
Meng X; Yin K; Wang J; Dong P; Liu L; Shen Y; Shen L; Ma Q; Lu H; Cai W
PLoS One; 2015; 10(6):e0130583. PubMed ID: 26107645
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.
Lee KY; Lin SW; Sun HY; Kuo CH; Tsai MS; Wu BR; Tang SY; Liu WC; Chang SY; Hung CC
PLoS One; 2014; 9(2):e88497. PubMed ID: 24551111
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
Kwara A; Lartey M; Sagoe KW; Xexemeku F; Kenu E; Oliver-Commey J; Boima V; Sagoe A; Boamah I; Greenblatt DJ; Court MH
J Clin Pharmacol; 2008 Sep; 48(9):1032-40. PubMed ID: 18728241
[TBL] [Abstract][Full Text] [Related]
10. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
Swart M; Skelton M; Ren Y; Smith P; Takuva S; Dandara C
Pharmacogenet Genomics; 2013 Aug; 23(8):415-27. PubMed ID: 23778320
[TBL] [Abstract][Full Text] [Related]
11. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
Wyen C; Hendra H; Vogel M; Hoffmann C; Knechten H; Brockmeyer NH; Bogner JR; Rockstroh J; Esser S; Jaeger H; Harrer T; Mauss S; van Lunzen J; Skoetz N; Jetter A; Groneuer C; Fätkenheuer G; Khoo SH; Egan D; Back DJ; Owen A;
J Antimicrob Chemother; 2008 Apr; 61(4):914-8. PubMed ID: 18281305
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.
Sarfo FS; Zhang Y; Egan D; Tetteh LA; Phillips R; Bedu-Addo G; Sarfo MA; Khoo S; Owen A; Chadwick DR
J Antimicrob Chemother; 2014 Feb; 69(2):491-9. PubMed ID: 24080498
[TBL] [Abstract][Full Text] [Related]
13. CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.
Reay R; Dandara C; Viljoen M; Rheeders M
OMICS; 2017 Aug; 21(8):465-473. PubMed ID: 28816644
[TBL] [Abstract][Full Text] [Related]
14. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.
Ramachandran G; Hemanth Kumar AK; Rajasekaran S; Kumar P; Ramesh K; Anitha S; Narendran G; Menon P; Gomathi C; Swaminathan S
Antimicrob Agents Chemother; 2009 Mar; 53(3):863-8. PubMed ID: 19124658
[TBL] [Abstract][Full Text] [Related]
15. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
Mukonzo JK; Okwera A; Nakasujja N; Luzze H; Sebuwufu D; Ogwal-Okeng J; Waako P; Gustafsson LL; Aklillu E
BMC Infect Dis; 2013 Jun; 13():261. PubMed ID: 23734829
[TBL] [Abstract][Full Text] [Related]
16. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.
Leger P; Dillingham R; Beauharnais CA; Kashuba AD; Rezk NL; Fitzgerald DW; Pape JW; Haas DW
J Infect Dis; 2009 Sep; 200(6):955-64. PubMed ID: 19659438
[TBL] [Abstract][Full Text] [Related]
17. Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism.
Sukasem C; Manosuthi W; Koomdee N; Santon S; Jantararoungtong T; Prommas S; Chamnanphol M; Puangpetch A; Sungkanuparph S
Infection; 2014 Jun; 42(3):469-74. PubMed ID: 24293076
[TBL] [Abstract][Full Text] [Related]
18. CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.
Maimbo M; Kiyotani K; Mushiroda T; Masimirembwa C; Nakamura Y
Eur J Clin Pharmacol; 2012 Mar; 68(3):267-71. PubMed ID: 21901344
[TBL] [Abstract][Full Text] [Related]
19. Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection.
Jamshidi Y; Moreton M; McKeown DA; Andrews S; Nithiyananthan T; Tinworth L; Holt DW; Sadiq ST
J Antimicrob Chemother; 2010 Dec; 65(12):2614-9. PubMed ID: 20952418
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
Sinxadi PZ; Leger PD; McIlleron HM; Smith PJ; Dave JA; Levitt NS; Maartens G; Haas DW
Br J Clin Pharmacol; 2015 Jul; 80(1):146-56. PubMed ID: 25611810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
